These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22819791)

  • 41. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
    Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
    J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stimulation of B-cell lymphopoiesis by interleukin-7 leads to aggravation of murine leishmaniasis.
    Gessner A; Will A; Vieth M; Schröppel K; Röllinghoff M
    Immunology; 1995 Mar; 84(3):416-22. PubMed ID: 7751025
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
    Scott P
    J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S; Ghaemimanesh F; Zahedifard F
    Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice.
    Pali-Schöll I; Szöllösi H; Starkl P; Scheicher B; Stremnitzer C; Hofmeister A; Roth-Walter F; Lukschal A; Diesner SC; Zimmer A; Jensen-Jarolim E
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):656-64. PubMed ID: 23523543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Splenectomy does not interfere with immune response to Leishmania major infection in mice.
    Maioli TU; Carneiro CM; Assis FA; Faria AM
    Cell Immunol; 2007 Sep; 249(1):1-7. PubMed ID: 18093575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
    Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis.
    San Román B; Irache JM; Gómez S; Gamazo C; Espuelas S
    Int Arch Allergy Immunol; 2009; 149(2):111-8. PubMed ID: 19127067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
    Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
    Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition.
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Colloids Surf B Biointerfaces; 2009 Nov; 74(1):37-44. PubMed ID: 19615870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice.
    Soudi S; Hosseini AZ; Hashemi SM
    Parasite Immunol; 2011 Oct; 33(10):561-71. PubMed ID: 21781137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
    Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
    Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.
    Flynn B; Wang V; Sacks DL; Seder RA; Verthelyi D
    Infect Immun; 2005 Aug; 73(8):4948-54. PubMed ID: 16041009
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
    Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
    Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.